The FDA made an update to their final guidance, “Postmarketing Adverse Event Reporting for Medical Products and Dietary Supplements During a Pandemic“. The guidance document now includes information for compounded drugs in Table 1:
| Type of Product or Application | Type of Report(s)/Statutory or Regulatory Timeframes(s) | FDA Recommended Reporting During a Pandemic With High Employee Absenteeism |
| Prescription drug products marketed without an approved New Drug Application (NDA): drugs compounded or repackaged by outsourcing facilites | 15-day Alert report, 15-day Alert – follow up/15 calendar days | Submit |
Have questions on this guidance? Our experts are here to help. Fill out “Fact Check Form” for answers to this or any other health or science-related subject. Our scientific experts are committed to providing answers.
